Podcasts about chief dr

Lurie Children's Department of Anesthesiology administers tens of thousands of anesthetics every year to treat children with a range of health conditions. Leading these efforts is Anesthesiologist-in-Chief Dr. Olutoyin Olutoye. In this episode, Dr. Olutoye walks through her and her team members' various roles before, during, and after an operation to ensure successful surgeries for even the tiniest babies. She also shares findings from her research in maternal-fetal anesthesiology as well as in anesthesia drugs and pediatric obesity.

Chris Cuomo speaks with Dr. Robert Redfield, former head of the CDC, about the origins and ongoing impact of COVID-19, including the role of U.S. and Chinese research in the virus's development. Redfield shares insights on government overreach, the effectiveness and side effects of vaccines, and the reality of long COVID, emphasizing the need for transparency and a comprehensive review of the pandemic response. Follow and subscribe to The Chris Cuomo Project on Apple Podcasts, Spotify, and YouTube for new episodes every Tuesday and Thursday: https://linktr.ee/cuomoproject Join Chris Ad-Free On Substack: http://thechriscuomoproject.substack.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Today joining me is my friend Russell Moore. He is RUNNING Christianity Today. I have followed him and what I love about Russell is that he was able to find a lane that a lot of Conservative Christians in America needed him to find.  He speaks to the problems of Christian Nationalism, calls things out when they are not Christ-like and isn't afraid to speak the truth.  He has a podcast called the Russell Moore show and recently launched a new book, Losing My Religion.  I think this conversation will help ALL of us, especially launching into the difficult conversations that are coming in 2024. —-- Listen to Russell's podcast HERE: https://pod.link/1074011166  Purchase his brand new book, Losing My Religion, HERE: https://www.penguinrandomhouse.com/books/709965/losing-our-religion-by-russell-moore/  Follow Russell on Twitter HERE: https://twitter.com/drmoore  Purchase your copy of my new book, How to Human, HERE: https://bit.ly/HowtoHumanNotes Let's keep in touch! Sign up for my newsletter to be the first to hear ALL my updates. https://bit.ly/MasFamiliaNotes Interested in advertising with us? Reach out here. _____ Thanks to our sponsors!  ATHLETIC GREENS: Athletic Greens is giving you a FREE 1-year supply of Vitamin D AND 5 free travel packs with your first purchase. Go to athleticgreens.com/HUMANHOPE. INDEED: Need to hire? You need Indeed. Visit Indeed.com/HUMANHOPE to start hiring now. BETTER HELP: This episode is sponsored by BetterHelp. Give online therapy a try at betterhelp.com/HUMANHOPE and get on your way to being your best self. HIYA HEALTH: Receive 50% off your first order at hiyahealth.com/HUMANHOPE

Today joining me is my friend Russell Moore. He is RUNNING Christianity Today. I have followed him and what I love about Russell is that he was able to find a lane that a lot of Conservative Christians in America needed him to find.  He speaks to the problems of Christian Nationalism, calls things out when they are not Christ-like and isn't afraid to speak the truth.  He has a podcast called the Russell Moore show and recently launched a new book, Losing My Religion.  I think this conversation will help ALL of us, especially launching into the difficult conversations that are coming in 2024. —-- Listen to Russell's podcast HERE: https://pod.link/1074011166  Purchase his brand new book, Losing My Religion, HERE: https://www.penguinrandomhouse.com/books/709965/losing-our-religion-by-russell-moore/  Follow Russell on Twitter HERE: https://twitter.com/drmoore  Purchase your copy of my new book, How to Human, HERE: https://bit.ly/HowtoHumanNotes Let's keep in touch! Sign up for my newsletter to be the first to hear ALL my updates. https://bit.ly/MasFamiliaNotes Interested in advertising with us? Reach out here. _____ Thanks to our sponsors!  ATHLETIC GREENS: Athletic Greens is giving you a FREE 1-year supply of Vitamin D AND 5 free travel packs with your first purchase. Go to athleticgreens.com/HUMANHOPE. INDEED: Need to hire? You need Indeed. Visit Indeed.com/HUMANHOPE to start hiring now. BETTER HELP: This episode is sponsored by BetterHelp. Give online therapy a try at betterhelp.com/HUMANHOPE and get on your way to being your best self. HIYA HEALTH: Receive 50% off your first order at hiyahealth.com/HUMANHOPE

Nov. 7, 2023 | Unifor members ratify Stellantis deal; Former NHTSA chief Dr. Mark Rosekind by Automotive News

"EXCLUSIVE: Pentagon UFO chief Dr Sean Kirkpatrick will be REPLACED by end of the year as whistleblowers accuse him of lying to the public and ignoring witnesses" IN THIS VIDEO: We take a deep dive into the Dailymail.com article, tweets from Ross Coulthart, Dr. Kirkpatrick's upcoming Hayden Center public UAP event and a statement from DOD spokesperson concerning Dr. Kirkpatrick, courtesy of Liberation Times.

Dr. Bicuspid https://www.drbicuspid.com/Dental Assistant Nation Podcast https://soundcloud.com/user-649058115 https://www.thecompliancedivas.com

In the 15th installment of the Inside JABA Series, Editor and Chief Dr. John Borrero and I chat with Drs. Lesleigh Stinson and Jesse Dallery about their novel application of a Contingency Management intervention. In this case, they used CM procedures to reduce excessive social media use.  Lesleigh is a Postdoctoral Researcher at the University of Florida's Center for Behavioral Economic Health Research, and Jesse is a Professor of Psychology, also at UF.  If you're not sure what Contingency Management is, don't worry, Lesleigh and Jesse cover the basics of it in this show. For additional information, you can also check out Jesse's previous appearance on the Inside JABA Series, where he and his colleagues used smartphone mediated technologies in conjunction with CM to reduce cigarette smoking.  This is a truly "Under the Dome" paper, and in our discussion of it, we touch on topics that include Internet Addiction, the recent APA Health Advisory on social media use, motivational interviewing, stages of change, and the benefits of single-case designs.  This podcast, as with all other Inside JABA Series shows, is available for continuing education. To learn more about that, click here. If you want to subscribe to JABA, click here.  We mentioned many resources and studies during this podcast. I've done my best to list them all below: Center for Behavioral Economic Health Research Jesse Dallery's lab: BHaT Lab Reducing problematic social media use via a package intervention (Stinson and Dallery, 2023) APA Health advisory on social media use in adolescence  N of 1 collaborative Screen Sanity (great resources for families) A behavior-analytic account of motivational interviewing (Christopher and Dougher, 2009) “I's” on the prize: A systematic review of individual differences in Contingency Management treatment response (Forster et al., 2020) Toward an era of impact of digital contingency management in the treatment of substance use disorders (Dallery et al., 2023) A Preliminary Evaluation of the Effects of a Contingency Management + Deposit Contract Intervention on Problematic Smartphone Use With College Students (Williams-Buttari et al., 2023) Contingency management for smartphone and social media use: a feasibility study (Stanley et al., 2021) The association between social media use and sleep disturbance among young adults (Levenson et al., 2016) How Motivational Interviewing Helps Reduce Alcohol Use Problems in Young Adults: Session 158 with Jim Murphy

Follow Jack Maxey

All-Natural TRINITY❤️PACK from Root Helps PROECT & DETOX Harmful Jabs, Graphene Oxide, ALS, Autism, Crohn's, the Poisonous Clot Shots with Iver & More

Do you think that the alarm raised by the DSS about some elements working to install an interim government holds any water? Are you of the opinion that it was the right approach to have adopted? Ponsah Fanap and Gilbert Joseph spoke to Chief Dr. Edinen Usoro about this course of event.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/jay-fm-podcast/message

“BE YOUR OWN NESARA - Become Who You Were Supposed to Be When You Came Into This World!" for Details

Descendant of Charles Carroll (Signed the Declaration of Independence), US Army Major Jim O'Connor retired as a Distinguished Combat Veteran Infantry Officer, received his M.B.A, then became a Priest & now Bishop in the Pre-Constantine Church who has successfully performed 11 Exorcisms.  At 70 he's beat Prostate Cancer, and benches 290 lbs at 6 reps/sets…a Man of God and Hero for Humanity, visit

Win a FREE Month's Supply of Root TRINITY❤️PACK from The Bling'd Buddha!

The three hosts have wildly different tangents to discuss. Some medical, some social, and one brief academic discussion about paralytics. Enjoy the nonsense. 

Win a FREE Month's Supply of Root TRINITY❤️PACK from The Bling'd Buddha!

We're Gifting a FREE TRINITY❤️PACK from Root! (No. Purchase. Necessary.)  Sign Up in 3 easy steps

We're Gifting a FREE TRINITY❤️PACK from Root! (No. Purchase. Necessary.)  Sign Up in 3 easy steps

Who Else Wants  a FREE TRINITY❤️PACK from Root! (No. Purchase. Necessary.)  Sign Up in 3 easy steps

“Q is My Religion”: Decorated Army Combat Medic & Whistleblower, SSG (R) Patrick Riley is the CEO of www.Reaper.Financial a Digital Asset Investment Firm whom filed an Amicus Brief to the SEC Case on behalf of  on Ripple's XRP https://www.reaper.financial/reaper-amicus-brief-in-sec-v-ripple/ Reaper Financial's mission is to help FREE Humanity of Debt Enslavement with their upcoming Debt Reaping tool. Watch Part 2 of 2 here now. . All-Natural TRINITY❤️PACK from Root Helps Detox ALS, Autism, Crohn's, the Poisonous Clot Shots with Iver & More

Sherri Divband is an Author, Animal Communicator, Intuitive Soul Reader, Reiki Master & co-Founder of www.AramisCreativeLearning.com  . All-Natural TRINITY❤️PACK from Root Helps Detox ALS, Autism, Crohn's, the Poisonous Clot Shots with Iver & More

Decorated Army Combat Vet, SSG (R) Patrick Riley is a brave Whistleblower & now CEO of www.Reaper.Financial a Digital Asset Investment Firm running on Ripple's XRP Ledger. This is Part 1 of a 2-part interview.  . All-Natural TRINITY❤️PACK from Root Helps Detox ALS, Autism, Crohn's, the Poisonous Clot Shots with Iver & More

Book a Free Silver & Gold Consultation with Dr. Kirk who was an Economic Advisor to Trump

WWG1WGA Part 3 of 3 with WHISTLEBLOWER, Veteran & Patriot who Exposes Hunter Biden's Laptop to the world. Follow Jack https://gettr.com/user/jack_maxey  . W.H.O. Chief Dr. Tedros on 26 Dec 2022 Admits Pfizer  CV-19 Vaxx "boosters are a bioweapon killing children in countries around the world!" TRINITY❤️PACK from Root Naturally Helps Detox Poisonous Clot Shots with Iver.  (ROOT is Tier 1 SpecOps Endorsed & Used by Olympians)

Dr. Thomas Zurbuchen who is the Associate Administrator at NASA Science. He actually just stepped down from his role after leading NASA science for over 6 years. He's behind many of the space initiatives over the past few years including the Mars Lander InSight and the James Webb Telescope.  Today's episode we discuss how old the universe is and if there is intelligent life somewhere in space, if we are living in a computer simulation or parallel universe, and how big our universe really is. It's not all space talk though, Thomas also shares how he makes decisions and deals with failure,  and the difference between making a mistake versus almost making a mistake and why it's so crucial to talk about both of these things. ------------------ Get ad-free listening, early access to new episodes and bonus episodes with the subscription version of the show The Future of Work Plus. To start it will only be available on Apple Podcasts and it will cost $4.99/month or $49.99/year, which is the equivalent to the cost of a cup of coffee.  ________________ Over the last 15 years, I've had the privilege of speaking and working with some of the world's top leaders. Here are 15 of the best leadership lessons that I learned from the CEOs of organizations like Netflix, Honeywell, Volvo, Best Buy, The Home Depot, and others. I hope they inspire you and give you things you can try in your work and life. Get the PDF here. --------------------- Get the latest insights on the Future of Work, Leadership and employee experience through my daily newsletter at futureofworknewsletter.com  Let's connect on social! Linkedin: http://www.linkedin.com/in/jacobmorgan8 Instagram: https://instagram.com/jacobmorgan8 Twitter: http://www.twitter.com/jacobm Facebook: https://www.facebook.com/FuturistJacob

WWG1WGA Part 2 of 3 with WHISTLEBLOWER, Veteran & Patriot who Exposes Hunter Biden's Laptop to the world. Follow Jack https://gettr.com/user/jack_maxey  . W.H.O. Chief Dr. Tedros on 26 Dec 2022 Admits Pfizer  CV-19 Vaxx "boosters are a bioweapon killing children in countries around the world!" TRINITY❤️PACK from Root Naturally Helps Detox Poisonous Clot Shots with Iver.  (ROOT is Tier 1 SpecOps Endorsed & Used by Olympians)

WWG1WGA Part 1 of 2 with WHISTLEBLOWER, Veteran, Patriot, Jack Maxey who Exposed Hunter Biden's Laptop to the world. Follow Jack https://gettr.com/user/jack_maxey  . . W.H.O. Chief Dr. Tedros on 26 Dec 2022 Admits Pfizer CV-19 Vaxx "boosters are a bioweapon killing children in countries around the world!" TRINITY PACK from Root Naturally Helps Detox Poisonous Clot Shots with Iver. (Trinity is Tier 1 SpecOps Endorsed & Used by Olympians)

We're back with the third episode of our image guided surgery video series! In this episode we're discussing deep brain electrode placement with ROSA robot in hybrid OR with some of our Interventional Radiology and Pediatric Neurosurgery colleagues at Cincinnati Children's Hospital. Our guests are Dr. Francesco Mangano, Dr. John Racadio and Nicole Hilvert. And we're joined by Dr. Denise Liu, radiology resident at University of Toledo. Hosts: Rod Gerardo, MD, Em Tombash, MD With image guided surgery, surgeon uses real-time images of the inside of the body during an operation. These images are generally produced by a combination of X-rays, ultrasound, CT's etc. Hybrid OR (operating room) at Cincinnati Children's is a collaboration between Radiology's Dr. John Racadio and Surgeon-in-Chief Dr. Daniel von Allmen. The hybrid OR offers imaging capabilities in a sterile operating room. It creates an environment for surgeons and interventional radiologists to combine their individual skills and expertise in order to benefit patient care. The room is equipped with X-ray, fluoroscopy (live X-ray), ultrasound and C-arm Cone Beam computed tomography (CBCT). Surgeons work together in the hybrid OR with interventional radiologists, who specialize in using these imaging technologies. Imaging can be performed just before the surgery to help plan the procedure, during the surgery to identify important anatomy or disease, and after the surgery to evaluate results in the hybrid OR. Any surgery requiring radiologic imaging including open and minimally invasive surgeries, may take place in the hybrid OR. The hybrid OR at Cincinnati Children's opened in 2018 and serves for general surgery, urology, orthopedic surgery, neurosurgery, pulmonology, and many more.

In our second episode of this new special series, we are honoured to be joined by Chief Dr. Robert Joseph, OC, OBC. Dr. Joseph is a hereditary Chief of the Gwawaenuk First Nation, is Ambassador for Reconciliation Canada where he has guided the Canadian Federal government through their residential school response. Dr. Joseph is a survivor of St. Michael's Residential School.  Dr. Joseph guides Tommy, Al, and Lawrence through the importance of creating safe space to converse and listen deeply in order for reconciliation to move forward. Dr. Joseph believes that technology, and platforms like podcasting, can be vehicles for moving reconciliation forward - specifically by giving opportunities for unheard voices and experiences from Indigenous peoples. This episode is full of practical advice to any listener, particularly for Indigenous and Canadian entrepreneurs who are looking to innovate and collaborate in this digital space. Gila'kasla! Follow us on Twitter: Wtncast Follow your co-hosts: Tommy | Al | Lawrence A very special thanks to Compulsion Soundlabs for sharing their musical talent, which you are hearing as the intro and outro music in this series! Subscribe for updates Email: wtncast@gmail.com Follow us on Apple Music and Spotify   Tommy and Al respectfully acknowledge that this show is recorded and produced on the traditional, unceded territories of the Anishinaabeg, Haudenosaunee, Chonnonton, and Lūnaapéewak peoples. London, Ontario, Canada is situated on their lands, a beautiful place that Tommy and Al are privileged to call home. Through this series, Tommy and Al aim to share their platform to create progressive, safe, and inclusive space to share the wisdoms, lessons, and experiences of Indigenous peoples from sea, to sea, to sea - in hopes of finding meaningful avenues to co-exist and function together online, in the spirit of love, courage, kindness, and reconciliation.

Ep 416 - BC Legends Guest: Carole Taylor By Stuart McNish   “British Columbia is rich with people of legendary status – people who looked the hardships of life in the eye and stared them down,” says Carole Taylor.  “Along the way, the tales of their seemingly impossible feats became folklore. In other words, they are larger than life.”   Carole Taylor, a legend in her own right, set out to document BC's living legends. She says, “I wanted to ensure we recognized and preserved the stories of these extraordinary women and men from them. I wanted to capture their personalities, their drive, their enthusiasm and great devotions.”   Taylor interviews artists, businesspeople, social advocates, environmentalists – along with others like Doug and Diane Clement, who convinced us to get off the couch and move; Ratana and Aaron Stephens, who guided us to consume organic food; Chief Dr. Robert Joseph, who showed us the path to reconciliation; and Jody Wilson-Raybould, who showed us what courage looks like when standing up to a Prime Minister.   Taylor says, “I focused on 26 extraordinary people who have contributed to our province and their reach has been global. These are the people Teddy Roosevelt was talking about, whose ‘faces are marred by dust and sweat and blood. People who err, who come up short time and again.' Jimmy Pattison, Brandt Louie, Dempsey Bob and Joe Segal are just a few of the BC Legends I sit down with this fall.”   We invited the host of “BC Legends with Carole Taylor” to join us for a Conversation That Matters about why preserving the stories of our legends is a gift to future generations – and future legends. Join us at a Conversations Live event, sign up for advance notice about upcoming events at conversationslive.ca

On today's Breitbart News Daily podcast, we begin with a discussion of Giorgia Meloni, who will become Italy's first female Prime Minister. She doesn't like illegal immigration, she doesn't like the globalists, she doesn't like high taxes, she doesn't like draconian lockdowns, but she does like big families. What's not to love? Everything apparently, if you're in the media or political establishment. She's branded "far right" and is being compared to Benito Mussolini. We get into it at the top of the show and then in more detail with our guest, Breitbart News' Rome Bureau Chief Dr. Tom Williams. Alex also discusses the Republicans beginning to roll out their 2023 agenda - assuming they, at least, take back the House. Good stuff there. Hillary Clinton compared normal Americans to Nazis. Also, Stacy Abrams claims fetal heartbeats are fake news, which is demonic. And Kamala Harris is attacking crisis pregnancy centers, which will contribute to the climate of violence we're already in. The longest witch hunt in history continues as well. 

In this introductory episode of the JCO Precision Oncology Conversations podcast, host Dr. Abdul Rafeh Naqash, MD, from the University of Oklahoma Stephenson Cancer Center, speaks with JCO Precision Oncology's founding Editor in Chief, Dr. James Ford, MD, of Stanford University. Dr. Naqash and Dr. Ford discuss how JCO Precision Oncology (JCO PO) started as a journal and how it has progressed since its launch in 2017. Dr. Ford dives into numerous JCO PO areas of interest, including liquid biopsy, genomics, biostatistics, and JCO PO-offered opportunities like the editorial fellowship program. GUEST BIO Dr. James Ford, MD, founding Editor in Chief of JCO Precision Oncology, received his MD degree from Yale University School of Medicine. He is currently Professor of Medicine (Oncology) and Genetics at Stanford University, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford University Medical Center." TRANSCRIPT Dr. Abdul Rafeh Naqash: Welcome to ASCO's JCO Precision Oncology Conversations, where we bring you the highlights and overview of precision oncology. Episodes will feature engaging conversations with authors of clinically relevant and highly significant articles in JCO Precision Oncology. These articles can be accessed at ascopubs.org/Journal/PO. Hi, my name is Dr. Abdul Rafeh Naqash and you are listening to the JCO Precision Oncology Conversations podcast. Today, I will be talking with Dr. James Ford, about JCO Precision Oncology. Dr. Ford is the editor-in-chief for JCO Precision Oncology. It's great to have you here today, Dr. Ford. Dr. James Ford: Thanks, Rafeh, so much for hosting me and for running this podcast series. I think it's going to be great for the journal and for our audience. Dr. Abdul Rafeh Naqash: Thank you so much, Dr. Ford. For the sake of our audience, could you introduce yourself with respect to your interest in medicine, oncology, and precision medicine specifically? Dr. James Ford: Sure! Well, I'm a physician-scientist, I trained at Stanford in medical oncology in genetics, and have spent my whole career here over 30 years. So, currently, I'm a professor of medicine in the division of oncology and genetics. I have focused my scholarly activities on cancer genetics and run a lab that's worked mostly in the field of DNA repair, and of course, this has evolved through the era of discovering and taking advantage of the fact that DNA damage response genes have turned out to be excellent targets for therapy in cancer. And so, this really combined my interest in the genetics of cancer and in targeting those biomarkers for therapy, which really has become the field of precision oncology. So, I run the Molecular Tumor Board here at Stanford and our Hereditary Cancer Genetics Program. So, that's really led to my interest in understanding both hereditary and somatic cancer genetics, and how we can use new targeted therapies to take advantage of understanding those biomarkers. Dr. Abdul Rafeh Naqash: Thank you so much for letting our audience know about all the work that you've done. You've definitely have been a leader in this field of cancer genomics and precision medicine. Talking about the intersection of where your interests met with starting JCO Precision Oncology, could you tell us since this is one of the sentinel episodes for our podcast series, could you elaborate on how you decided to start JCO Precision Oncology as a journal? And what was your vision of how you would shape the journal as it continued to progress over the subsequent years? Dr. James Ford: Sure! Well, the credit really goes to ASCO for the vision to start this journal about 6 or 7 years ago. ASCO decided to start adding some sister journals to its very successful flagship journal, the Journal of Clinical Oncology. And one of those, it was decided that an area, burgeoning area of interest that would be useful to our community is around precision oncology. And so, they launched a search release for a founding editor for what was named then JCO Precision Oncology, and I was fortunate enough to be chosen to be that founding editor. So, the journal started publishing just 5 years ago, right about now, this is our 5th anniversary, really, with the goal of focusing on research and reports, particularly around the clinical use of profiling tumors in individuals, as a way to advance therapies as a general scope. So, this was to add to the value that JCO, the parent journal, already has in thinking about this field that's taking advantage of n-of-1 study or of sometimes small series of studies because of the rarity of some of these genomic changes. So, scientific advances that we can take advantage of clinically, that perhaps don't fit into the traditional large phase three randomized study that reached the level of JCO, or some other journals. And I think we've seen since starting that this really has addressed an excellent niche in the field and allowed an area to publish really excellent research that doesn't always fit into some of the other journals. So, I guess the first step really then 5 years ago, 5-6 years ago, when we started this journal, was really with the truly excellent staff at ASCO and JCO, which helped launch this journal to put together our initial associate editors and board of editors, which I think truly has been one of the best parts of this whole general experience. We have the leaders in the younger generation of cancer therapy researchers and oncologists focused on precision oncology, all gathered together in this journal. And it's actually one of the most fun things about doing this is working with this great group. Of course, we've been adding to that over the years, but really, our initial core group has stayed with us. And together with the great staff and all the reviewers that have helped with this really started to put a focus on the sorts of papers and the kind of areas that it's really useful for us to publish them. Dr. Abdul Rafeh Naqash: Definitely, as you mentioned, Dr. Ford, the success of a journal, like JCO PO involves a large team that works behind the scene, including yourself and many others, as well as the reviewers who do their due diligence in helping us get the right content out there. So, you mentioned about your interest in DNA damage and you mentioned about your interest in cancer genomics. Based on how you have seen this whole field evolve, what is your understanding of how we can incorporate more and more precision medicine from an early therapeutics' standpoint and also from a standard of care standpoint? Where do you see all that going from a testing standpoint, as well as a clinical application standpoint? Dr. James Ford: Well, I think one of the really interesting aspects of the tenure of this journal has been moving from what still is and largely was a research-based approach to cancer therapeutics using genomic and other types of molecular profiling of tumors to try to select therapies in the best way for individual patients to taking that to hopefully becoming standard of care, a better understanding how to apply that to certain individual patients, as well as have groups of patients, how to best use genomic biomarkers, and how to best encourage the development of new targeted cancer therapies for that type of use. So, I think an exciting aspect has been also profiling new clinical trial methods, and new biostatistical ways of looking at this kind of data that can't always be done in traditional large randomized trials – how to advance the field clinically, based on really the incredible technological underpinnings of the field. And so, that's required, I think, some novel and different ways of looking at and publishing data. So, of course, we are publishing original reports of excellent science, often based on preclinical findings, but always trying to find those that certainly have applications to the clinic and preferably have been tried in the clinic and shown advancements that we can take advantage of, but also, I think, importantly, has been publishing case reports, and other ways of highlighting smaller successes in the field that can lead to further larger clinical investigations. And as you know, it's hard to find journals and places where that can be published. Of course, we're quite restrictive in the kind of case reports we publish, we want to do those that have really high educational value or high predictive value for future clinical use. But I think precision oncology is one area of medicine, where looking at individual cases can be very revealing for future clinical benefit. Another thing we're doing and we founded was a series of what we call molecular tumor boards, and that really is just a description of a case or cases that are written from a Molecular Tumor Board group and describes the process of using very complicated genomic test reports and expertise from a number of physicians and scientists in interpreting that to best try to advance the therapy for a patient or group of patients. And I think that helps show to clinicians the value of a molecular tumor board or this kind of approach to analyzing both the lab-based genomic data and clinical experience and use of molecular pathology and pathologist experience, to synthesize these kinds of cases, and I think these have been very revealing as well and useful to the literature. Dr. Abdul Rafeh Naqash: Absolutely! I completely agree with you. And based on everything that you mentioned JCO Precision Oncology has definitely had a lot of significant and important submissions that have come out, and as our viewers might know, we have our most recent impact factor which is close to 5.5. So, congratulations to you Dr. Ford, and I guess the rest of the team that worked behind the scene for accomplishing this. Do you have any additional thoughts on anything that the listeners should know on the kind of content that you'd be interested in getting submissions for over the next 6 months to a year so that we have an understanding from the listeners of what kind of content is most acceptable like you mentioned earlier? Dr. James Ford: Sure! Well, as I said, we publish a number of types of articles, obviously, original scholarly reports and investigations, case reports, Molecular Tumor Board discussions, editorials, and commentaries on papers in our journal or others or areas in the field that are interesting. I think we have a healthy dialogue happening in the journal with discussions and responses from authors regarding papers we publish. This is an online journal and so we really try to publish in real-time and have an interactive forum for that. So, of course, anyone is welcome to submit ideas or commentaries on areas in the field that we think are important or should be advanced. So, we serve as a forum for that discussion as well as publishing traditional articles. I would say something that we've tried to focus on and we'll continue to do so is every year having one or several particular areas of interest that we're recruiting articles or commentaries, review articles about. Over the last couple of years, for example, we had a series very much focused on liquid biopsies and how the use of circulating tumor DNA is really revolutionizing precision oncology. We had a wonderful set of articles from our biostats editor, Ying Lu, on new biostatistical approaches to clinical trials in the area of precision oncology, thinking about the particular needs in that area. I think in the next year or so, we are launching a series right now on the use of genomic profiling, molecular profiling in earlier-stage cancer, and how to use that information for choosing or defining the correct adjuvant therapy in early cancers or using it before the metastatic setting, trying to move the process up. Is it appropriate? Where should it be used? How best to use that? It is quite an open area that I think we're going to make great advances on in the next few years. I think an area of great interest is how to think about combining targeted therapies in a precision oncology approach. How do you test preclinically? And then, of course, clinically, multiple agents together to take advantage of genomic biomarkers to advance therapies and how to test that in the clinic which is, of course, a great challenge. How to rationally pick those agents that we think might provide synergy. Of course, an area of great interest for everybody is thoughts around diversity, equity, and inclusion in clinical medicine in general, but for us, specifically, in best understanding genetics and genomics of diverse populations, how to be most inclusive in our clinical trial process, and testing of these approaches. And I think we've had a number of very thoughtful articles in this space and encourage more in this area as well. Dr. Abdul Rafeh Naqash: Thank you so much. Those are all amazing things that the journal is trying to implement. All those topics that you mentioned are extremely important and very interesting as far as precision medicine goes. Shifting gears a little bit. Dr. Ford, could you tell us about the JCO Precision Oncology Editorial Fellowship? As you know, I am a product of that editorial fellowship, where I was paired with Dr. Rodrigo Dienstmann, and it was an amazing experience. For the sake of our listeners, early career investigators, fellows, could you tell us a little bit about what this fellowship is and how that integrates into how we are trying to shape JCO Precision Oncology and the next generation of precision medicine specialists? Dr. James Ford: Sure! Well, I think this has been a really exciting and fun area for the journal. And in fact, for all the ASCO journals. ASCO instituted a fellowship program several years ago, in which mostly senior fellows, and junior faculty members in related fields, apply to work with one of the journals over the course of a year. And so, for the past several years, we've been fortunate enough to have two editorial fellows assigned to JCO PO that have worked with our associated editors throughout the process, really to learn how to not only review and manage manuscript submissions, but to best think about some of the issues we've been talking about like, how to show tape the direction of a journal, how to think about what are the most important areas in a field that we want to highlight, and hopefully can support. And it's been a great experience. We the editors have loved working with the fellows, really all of the fellows have gone on and continued in this field in academics across the country, and across the world, and a number have gone on to continue working with the journal like you, Rafeh. It's been terrific, as our audience knows. And you mentioned you were a fellow and now joined the journal as part of the editorial staff to run this whole social media program. And a number of our other fellows have joined the editorial board and continue to work with us and to really contribute to the field. So, I think that program has not only been really helpful to the folks who participated in it but to the field and to our journal in developing new talent and recruiting them to the field, so, very successful! We've even taken another step in the journals towards this and the board of editors themselves are serving as mentors to other folks and mostly fellows in medical oncology and related fields, simply to learn how to become better reviewers of papers, and go through that process with a little guidance from the editorial group. And of course, this really helps us to deepen our pool of expert reviewers and referees for journals. So, I think this process has been iterative and very beneficial to the journal. Dr. Abdul Rafeh Naqash: Definitely, I totally connected with that, Dr. Ford, as you mentioned, I was a JCO PO editorial fellow, worked with Dr. Dienstmann and yourself, and it led to subsequent interactions and roles within JCO PO, which has been amazing. I would definitely encourage all the listeners, whoever is interested in applying, if they fit the eligibility criteria to definitely apply, to the ASCO Editorial Fellowship, especially JCO Precision Oncology, given my bias towards the journal. It was amazing talking to you, Dr. Ford. Do you have any closing thoughts on what our listeners should be expecting as far as the journal or any other suggestions that you have for potential submissions out there, any other thoughts that you would like to share with our audience? Dr. James Ford: Well, thanks, Rafeh, for having me and for conducting this interview. It's been a pleasure to talk about the journal. I would conclude by saying that this has been a great experience for me, and I think our whole editorial group, to start and to develop this journal, and really see how both it can grow itself and how I think it contributes to the growth of the field and serve as a nidus for our field in exchanging information and developing new ideas and thoughts that can benefit our patients. So, I just would like to thank all of our group, our reviewers, and certainly the authors and folks that have submitted articles and ideas to the journal. I think it's making a difference. And I think the field, in general, is at a very exciting point and is making a difference for patient care, and will continue to do so with new technologies and new therapies and new ways to incorporate those. So, I think we've shown that this has been a useful journal for the field and I think I'm very excited about where things are going to go. Dr. Abdul Rafeh Naqash: Thank you so much. I completely echo your thoughts. I would like to encourage the listeners to stay tuned for subsequent author conversations, and other interactive conversations that we'll have on our JCO Precision Oncology Conversations podcast, subsequently. Thank you so much for joining us today, Dr. Ford. Dr. James Ford: Thank you. Dr. Abdul Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. You can find all our shows, including this one, at asco.org/podcasts, or wherever you get your podcasts. To stay up to date, be sure to follow and share JCO PO content on Twitter. The Twitter handle is @JCOPO_ASCO. All JCO PO articles and series can be found at ascopubs.org/Journal/PO.   The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Disclosures Dr. James Ford's institution receives research funding from Genentech, AstraZeneca, Puma Biotechnology, Pfizer, Merus, Bayer, and Incyte.      

In this episode, Dr. Chiavaccini interviews the coEditor in Chief of Veterinary Anaesthesia and Analgesia, Dr. Rachel Bennet.

We're back with the second episode of our image guided surgery video series! In the second part of this episode we're discussing lung nodule resection in hybrid OR with some of our Interventional Radiology and Pediatric Surgery colleagues at Cincinnati Children's Hospital. Our guests are Dr. Anusua "Roshni" Dasgupta, Dr. John Racadio, Dr. Neil Johnson and Nicole Hilvert. And we're joined by Dr. Denise Liu, radiology resident at University of Toledo. Hosts: Rod Gerardo, MD, Em Tombash, MD With image guided surgery, surgeon uses real-time images of the inside of the body during an operation. These images are generally produced by a combination of X-rays, ultrasound, CT's etc. Hybrid OR (operating room) at Cincinnati Children's is a collaboration between Radiology's Dr. John Racadio and Surgeon-in-Chief Dr. Daniel von Allmen. The hybrid OR offers imaging capabilities in a sterile operating room. It creates an environment for surgeons and interventional radiologists to combine their individual skills and expertise in order to benefit patient care. The room is equipped with X-ray, fluoroscopy (live X-ray), ultrasound and C-arm Cone Beam computed tomography (CBCT). Surgeons work together in the hybrid OR with interventional radiologists, who specialize in using these imaging technologies. Imaging can be performed just before the surgery to help plan the procedure, during the surgery to identify important anatomy or disease, and after the surgery to evaluate results in the hybrid OR. Any surgery requiring radiologic imaging including open and minimally invasive surgeries, may take place in the hybrid OR. The hybrid OR at Cincinnati Children's opened in 2018 and serves for general surgery, urology, orthopedic surgery, neurosurgery, pulmonology, and many more. Don't forget to like and subscribe to see more entertaining medical educational videos! Follow StayCurrent MD on social media! Instagram: www.instagram.com/staycurrentmd/ Twitter: www.twitter.com/StayCurrentMD Facebook: www.facebook.com/staycurrentsurgery Don't forget to like and subscribe to see more entertaining medical educational videos! See more lectures, articles, and more on the Stay Current app: https://www.globalcastmd.com/stay-current-app-download

"Middle Ground with JLE L.L.C." Podcast "Where We Treat You Like Family" welcomes Diversity, Equity, Inclusion, and Anti-Racism Advocate, Dissertation Editor & Coach, & DISSERTATION ALCHEMIST LLC Founder/Editor-In-Chief Dr. Dawn Dice Renner as she shares her journey.

In this episode, Dr. Raul Coimbra shares with us his vision for the the Journal of Trauma & Acute Care Surgery.

Senior Care Pharmacist Podcast host Amie Blaszczyk interviews editor in chief of The Senior Care Pharmacist, Dr. Chris Alderman, about his editorial re: the "other pandemic" (diabetes). https://www.ascp.com/page/SenioRxRadio    See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Police Chief Dr. Lance Spivey talks with Billy and Paulie about how forward thinking has lead to better professional development for his officers as well as high retention rates within his organization. The group talk about police reform, antecedent interventions to increase morale, and tying reinforcement to better job outcomes for greater success.

In this episode, we sit down with MELG's new Editor-In-Chief, Dr. Janine A. Clark, to discuss the future of MELG and opportunities to engage with the journal.

In this episode of The Nurse Practitioner Podcast, Dr. Jamie Newland, Editor-In-Chief of The Nurse Practitioner, discusses her work with the journal, her career, and our new department: Global Perspectives.